Bluejay Diagnostics, Inc. (BJDX) company profile
Close on Nov 17, 2026Market cap $9.63MP/E –Yield –
About Bluejay Diagnostics
Surgical & Medical Instruments & Apparatus, SIC 3841
Bluejay Diagnostics, Inc. is a medical diagnostics company dedicated to improving patient care in critical healthcare environments, particularly for individuals diagnosed with sepsis. The company is actively developing point-of-care, rapid diagnostic tests that use whole blood samples with its proprietary Symphony technology platform. This platform comprises a specialized centrifugal analyzer and single-use protein detection cartridges designed to measure key biomarkers, with its lead product candidate focused on interleukin-6 testing. Bluejay Diagnostics intends to serve healthcare providers operating in critical care environments, with a particular focus on intensive care units and emergency rooms within acute care facilities.
The company focuses its commercialization plans on large critical care hospital facilities situated across the United States. Its technology relies on cartridge manufacturing and development operations conducted through a partner facility located in Japan. Bluejay Diagnostics maintains its corporate headquarters in Acton, Massachusetts.
Summary of the business section of Bluejay Diagnostics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Bluejay Diagnostics, Inc.
- Founded
- 2015
- Headquarters
- Acton, MA
- Address
- 360 Massachusetts Avenue, Suite 203 01720
- Phone
- (978) 631-0152
- Website
- bluejaydx.com
- Employees
- 6, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Wolf & Company, P.C., Boston, Massachusetts
Stock & identifiers
- Ticker
- BJDX
- Exchange
- Nasdaq
- IPO date
- Nov 12, 2021
- Shares outstanding
- 4M, Aug 7, 2026
- Public float
- $2.57M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-4 reverse, Jan 29, 2026; 1-for-50 reverse, Mar 31, 2025; 1-for-50 reverse, Nov 18, 2024; 1-for-8 reverse, Jun 20, 2024; 1-for-20 reverse, Jul 24, 2023
- SEC CIK
- 1704287
- CUSIP
- 095633608
- ISIN
- US0956336087
- FIGI
- BBG012TKJCJ1
- Share class FIGI
- BBG012TKJDC6
- EIN
- 47-3552922
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Indranil Dey | President and CEO, Director | 40,649 |
| Svetlana Dey | Director | 12,628 |
| Douglas Clark Wurth | Director | 1,121,491 |
| Fred S. Zeidman | Director | 12,500 |
| Donald R. Chase | Director | 12,525 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|
| Neil Dey President & Chief Executive Officer | $328.19K | $137.50K | $7.86K | $473.56K | +63% |
| Jason Cook Chief Technology Officer | $111.60K | – | $214.64K | $326.24K | +30% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 12, 2021
- Offer price
- $10.00
- Securities offered
- 2,160,000
- Gross proceeds
- $21.60M
- Exchange
- Nasdaq
- First trading day
- Nov 10, 2021
- First-day close
- $5.32-46.8%
- Lock-up ends (est.)
- May 9, 2022
“Per Unit (2) Total (3) Public offering price $ 10.00 $ 21,600,000 Underwriting discounts (1) $ 0.80 $ 1,728,000 Proceeds to us, before expenses $ 9.20 $ 19,872,000 ____________ (1) The underwriters will receive compensation in addition to the underwriting discounts and commissions.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 2, 2026, we have 6 full-time employees, which includes one executive officer.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 28, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 4, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 27, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 28, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 12, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 5, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?